Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer

Modulation of T cell immune checkpoints combined with inhibition of chemokine receptors on myeloid-derived suppressor cells can reprogram the highly suppressive tumor immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), and generates durable complete responses in a PDAC mouse model. These results provide a testable clinical regimen for human PDAC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Combined therapeutic targeting of 41BB, LAG3 and CXCR2 in PDAC.


  1. Ying, H. et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 30, 355–385 (2016). A review article that presents the key mechanisms underlying growth, metastasis and therapeutic resistance of PDAC, including the complexity of immune regulation in the tumor microenvironment.

    Article  CAS  Google Scholar 

  2. Bear, A. S., Vonderheide, R. H. & O’Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788–802 (2020). A review article that describes strategies that may be rationally combined to overcome immune resistance in PDAC.

    Article  CAS  Google Scholar 

  3. O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma. JAMA Oncol. 5, 1431–1438 (2019). This paper reports the lack of clinical efficacy of anti-PD1 and anti-CTLA4 immunotherapy in PDAC.

    Article  Google Scholar 

  4. Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845 (2016). This paper provides the pre-clinical rationale for targeting CXCR2 on myeloid cells in combination with immunotherapy in PDAC.

    Article  CAS  Google Scholar 

  5. Van Der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single cell analysis. Nat. Rev. Cancer 20, 218–232 (2020). A review article that describes the relationship between various T cell states and therapeutic response to ICT.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumour immunity and durable response in pancreatic cancer. Nat. Cancer (2022).

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer. Nat Cancer 4, 7–8 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing